Serina Therapeutics Receives FDA Clearance for SER-252 IND
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy SER?
Serina Therapeutics announced that the FDA has cleared its investigational new drug application for SER-252, an investigational therapy for advanced Parkinson's disease. The IND clearance allows Serina to proceed with regulatory and site-level activities to support initiation of a planned Phase 1b registrational clinical study evaluating SER-252 in patients with advanced Parkinson's disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SER
Wall Street analysts forecast SER stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.800
Low
11.00
Averages
11.00
High
11.00
Current: 1.800
Low
11.00
Averages
11.00
High
11.00
About SER
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Serina Therapeutics Doses First Patient in Parkinson's Trial
- Trial Commencement: Serina Therapeutics has dosed the first patient in its Phase 1b registrational clinical trial for SER-252, aimed at evaluating safety and preliminary efficacy, thereby providing a new treatment option for patients with inadequately controlled advanced Parkinson's disease.
- FDA Approval Milestone: In January 2026, the U.S. FDA cleared the Investigational New Drug application for SER-252, marking a significant milestone in the drug's clinical development and laying the groundwork for the subsequent 505(b)(2) NDA pathway.
- Partnership Development: Serina has partnered with Parkinson's Australia and Neuroscience Trials Australia to support patient identification and enrollment activities, which is expected to accelerate patient recruitment for the clinical trial and enhance research efficiency.
- Financial Condition Shift: For the third quarter ended September 30, 2025, Serina reported a net loss of $4.59 million, or $0.45 per share, a significant decline from a net profit of $1.41 million in the same period last year, reflecting ongoing pressure from R&D investments.
See More
Serina Therapeutics Enrolls First Patient in Australia for SER-252 Trial
- Clinical Trial Launch: Serina Therapeutics has successfully enrolled its first patient in Australia, marking the official start of its Phase 1b registrational trial for SER-252 targeting advanced Parkinson's disease, with dosing expected to commence in Q1 2026, indicating positive progress in clinical development.
- Partnership Development: The company has established collaborations with Parkinson's Australia and Neuroscience Trials Australia to support patient identification and recruitment, ensuring efficient trial execution and enhancing Serina's operational capabilities in clinical trials.
- FDA Strategic Alignment: Serina has aligned with the FDA to pursue a 505(b)(2) NDA pathway for its registrational development, indicating regulatory support in its drug development process and strengthening its competitive position in the market.
- Platform Technology Advantage: Serina's POZ platform technology offers improved control over drug release and safety, expected to enhance the pharmacokinetic profiles of existing drugs, addressing the urgent market demand for new therapies and further driving innovation in the neurological disease sector.
See More
Navigating the New FDA Era: 2026 Strategic Priorities
- CEO Presentation Event: Steven Ledger, CEO of Serina Therapeutics, will present at Tribe Public's webinar on February 4, 2026, discussing FDA initiatives that may impact drug development timelines and review processes, potentially altering investor expectations.
- Technology Platform Overview: Serina's POZ Platform™ aims to optimize the efficacy and safety of drug candidates across various modalities, including small molecules, RNA therapeutics, and antibody-drug conjugates, showcasing its potential in treating neurological diseases.
- Industry Impact Analysis: The event will provide attendees with the opportunity to directly question management, reflecting investor concerns regarding FDA policy changes that could influence investment decisions in the biotechnology sector.
- Company Background Information: Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, focused on developing drug candidates for neurological diseases, demonstrating its innovative capabilities in the life sciences field.
See More
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
- Disappointing Delivery Numbers: Xpeng Inc reported delivering 20,011 vehicles in January 2026, a figure that, while substantial, fell short of market expectations, leading to a decline in investor confidence.
- Stock Price Reaction: Following the disappointing delivery results, Xpeng's stock dropped 5.6% in pre-market trading to $16.97, reflecting concerns about the company's future performance among investors.
- Overall Market Trend: U.S. stock futures were lower, with Dow futures falling around 100 points, indicating a cautious market sentiment that could further impact investor attitudes towards Xpeng.
- Industry Impact: The delivery figures from Xpeng may negatively affect overall confidence in the electric vehicle market, especially in an increasingly competitive landscape, prompting investors to reassess their strategies.
See More
DarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
- Significant Revenue Growth: DarkIris Inc reported a year-over-year revenue increase of 27.3% for FY25, reaching $10.08 million compared to $7.92 million in FY24, indicating strong market performance and growth potential.
- Stock Price Surge: Following the positive earnings report, DarkIris shares jumped 104.2% in pre-market trading to $0.68, reflecting investor optimism about the company's future prospects.
- Positive Market Reaction: The release of this earnings report has significantly increased market attention on DarkIris, enhancing investor confidence in its continued growth and potentially attracting more capital inflow.
- Optimistic Industry Outlook: The robust performance of DarkIris not only strengthens its market position but may also provide more opportunities for future financing and expansion plans, further solidifying its competitive edge in the industry.
See More
Serina Therapeutics Receives FDA Clearance for IND Application
- FDA IND Clearance: Serina Therapeutics announced that its IND application for SER-252 has been cleared by the FDA, allowing the company to proceed with preparations for a planned Phase 1b registrational study, which is expected to significantly advance treatment options for Parkinson's disease patients.
- Stock Surge: Following the FDA clearance announcement, Serina's shares surged over 70% in pre-market trading, reflecting strong market optimism for the therapy, particularly after experiencing a setback in November 2025 when the FDA placed a clinical hold on its trials.
- Trial Design Support: The FDA had previously provided written feedback supporting Serina's proposed registrational trial design under the 505(b)(2) NDA pathway, indicating a clear path forward for the therapy to address significant unmet medical needs.
- Market Sentiment Shift: Following the announcement, investor sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', accompanied by a surge in message volume, indicating strong market interest and potential investment opportunities for SER-252.
See More
Serina Therapeutics Doses First Patient in Parkinson's Trial
- Trial Commencement: Serina Therapeutics has dosed the first patient in its Phase 1b registrational clinical trial for SER-252, aimed at evaluating safety and preliminary efficacy, thereby providing a new treatment option for patients with inadequately controlled advanced Parkinson's disease.
- FDA Approval Milestone: In January 2026, the U.S. FDA cleared the Investigational New Drug application for SER-252, marking a significant milestone in the drug's clinical development and laying the groundwork for the subsequent 505(b)(2) NDA pathway.
- Partnership Development: Serina has partnered with Parkinson's Australia and Neuroscience Trials Australia to support patient identification and enrollment activities, which is expected to accelerate patient recruitment for the clinical trial and enhance research efficiency.
- Financial Condition Shift: For the third quarter ended September 30, 2025, Serina reported a net loss of $4.59 million, or $0.45 per share, a significant decline from a net profit of $1.41 million in the same period last year, reflecting ongoing pressure from R&D investments.
See More
Serina Therapeutics Enrolls First Patient in Australia for SER-252 Trial
- Clinical Trial Launch: Serina Therapeutics has successfully enrolled its first patient in Australia, marking the official start of its Phase 1b registrational trial for SER-252 targeting advanced Parkinson's disease, with dosing expected to commence in Q1 2026, indicating positive progress in clinical development.
- Partnership Development: The company has established collaborations with Parkinson's Australia and Neuroscience Trials Australia to support patient identification and recruitment, ensuring efficient trial execution and enhancing Serina's operational capabilities in clinical trials.
- FDA Strategic Alignment: Serina has aligned with the FDA to pursue a 505(b)(2) NDA pathway for its registrational development, indicating regulatory support in its drug development process and strengthening its competitive position in the market.
- Platform Technology Advantage: Serina's POZ platform technology offers improved control over drug release and safety, expected to enhance the pharmacokinetic profiles of existing drugs, addressing the urgent market demand for new therapies and further driving innovation in the neurological disease sector.
See More
Navigating the New FDA Era: 2026 Strategic Priorities
- CEO Presentation Event: Steven Ledger, CEO of Serina Therapeutics, will present at Tribe Public's webinar on February 4, 2026, discussing FDA initiatives that may impact drug development timelines and review processes, potentially altering investor expectations.
- Technology Platform Overview: Serina's POZ Platform™ aims to optimize the efficacy and safety of drug candidates across various modalities, including small molecules, RNA therapeutics, and antibody-drug conjugates, showcasing its potential in treating neurological diseases.
- Industry Impact Analysis: The event will provide attendees with the opportunity to directly question management, reflecting investor concerns regarding FDA policy changes that could influence investment decisions in the biotechnology sector.
- Company Background Information: Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, focused on developing drug candidates for neurological diseases, demonstrating its innovative capabilities in the life sciences field.
See More
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
- Disappointing Delivery Numbers: Xpeng Inc reported delivering 20,011 vehicles in January 2026, a figure that, while substantial, fell short of market expectations, leading to a decline in investor confidence.
- Stock Price Reaction: Following the disappointing delivery results, Xpeng's stock dropped 5.6% in pre-market trading to $16.97, reflecting concerns about the company's future performance among investors.
- Overall Market Trend: U.S. stock futures were lower, with Dow futures falling around 100 points, indicating a cautious market sentiment that could further impact investor attitudes towards Xpeng.
- Industry Impact: The delivery figures from Xpeng may negatively affect overall confidence in the electric vehicle market, especially in an increasingly competitive landscape, prompting investors to reassess their strategies.
See More
DarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
- Significant Revenue Growth: DarkIris Inc reported a year-over-year revenue increase of 27.3% for FY25, reaching $10.08 million compared to $7.92 million in FY24, indicating strong market performance and growth potential.
- Stock Price Surge: Following the positive earnings report, DarkIris shares jumped 104.2% in pre-market trading to $0.68, reflecting investor optimism about the company's future prospects.
- Positive Market Reaction: The release of this earnings report has significantly increased market attention on DarkIris, enhancing investor confidence in its continued growth and potentially attracting more capital inflow.
- Optimistic Industry Outlook: The robust performance of DarkIris not only strengthens its market position but may also provide more opportunities for future financing and expansion plans, further solidifying its competitive edge in the industry.
See More
Serina Therapeutics Receives FDA Clearance for IND Application
- FDA IND Clearance: Serina Therapeutics announced that its IND application for SER-252 has been cleared by the FDA, allowing the company to proceed with preparations for a planned Phase 1b registrational study, which is expected to significantly advance treatment options for Parkinson's disease patients.
- Stock Surge: Following the FDA clearance announcement, Serina's shares surged over 70% in pre-market trading, reflecting strong market optimism for the therapy, particularly after experiencing a setback in November 2025 when the FDA placed a clinical hold on its trials.
- Trial Design Support: The FDA had previously provided written feedback supporting Serina's proposed registrational trial design under the 505(b)(2) NDA pathway, indicating a clear path forward for the therapy to address significant unmet medical needs.
- Market Sentiment Shift: Following the announcement, investor sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', accompanied by a surge in message volume, indicating strong market interest and potential investment opportunities for SER-252.
See More
